查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1611323

类风湿性关节炎诊断测试市场：按测试类型、最终用户划分 - 2025-2030 年全球预测

Rheumatoid Arthritis Diagnosis Tests Market by Test Type (Monitoring Rheumatoid Arthritis Treatment Efficiency Tests, Serology Test), End-User (Diagnostic Centers, Hospitals & Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

类风湿性关节炎诊断测试市场2023年估值为29.8亿美元，预计2024年将达30.8亿美元，复合年增长率为4.69%，预计到2030年将达到41.1亿美元。

类风湿性关节炎(RA) 诊断测试包括一系列诊断程序，旨在检测 RA（一种影响关节的慢性自体免疫疾病）的存在和进展。进行这些检查的必要性源于 RA 对生活品质的影响，以及如果不治疗可能导致关节损伤和全身併发症的可能性。主要应用包括类风湿因子 (RF) 等血液检测、抗环瓜氨酸肽 (抗 CCP) 抗体检测以及 X 光和 MRI 等影像检查。最终用途广泛，包括医院、诊断实验室和学术研究机构。推动市场成长的主要因素是 RA 盛行率的增加、诊断技术的改进以及患者和医疗保健提供者意识的提高。人口老化和生物标誌物的进步也有助于市场扩张。新的商机存在于快速、准确和微创诊断测试的开发以及远端监控的远端医疗应用的扩展中。

主要市场统计
基准年[2023] 29.8亿美元
预计年份 [2024] 30.8亿美元
预测年份 [2030] 41.1亿美元
复合年增长率（%） 4.69%

然而，先进诊断测试的高成本、误报和漏报的风险以及低收入地区的意识低等挑战正在阻碍市场成长。报销问题也会限制测试的机会。为了应对这些挑战，技术创新应专注于具有成本效益的诊断解决方案，提高测试的敏感性和特异性，并透过数位健康平台扩大患者的访问范围。诊断公司、医疗保健提供者和科技公司之间的合作可以促进诊断准确性和可近性的显着提高。同时，透过专注于利用人工智慧和基因研究的个人化医疗保健，我们可以期待量身定制的 RA 管理。新型生物标记的研究和多组体学方法的整合也为创新提供了肥沃的土壤。市场是竞争性的、技术主导的，因此投资新技术、优先考虑伙伴关係关係并解决地区健康差异的公司可能会增强其市场地位。总之，RA 诊断测试市场有望透过技术进步和策略措施实现成长，同时面临成本和可近性方面的挑战。

市场动态：快速发展的类风湿性关节炎诊断测试市场的关键市场洞察

供需的动态交互作用正在改变类风湿性关节炎诊断测试市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球类风湿性关节炎盛行率不断上升
    • 增加 RA 治疗和管理的支出
    • 政府和全球组织针对 RA 所进行的宣导活动
  • 市场限制因素
    • 患者不愿接受 RA 医疗服务
  • 市场机会
    • 改进 MRI、超音波和 HR-pQCT影像检查并开发血清生物标记组
    • 正在进行的 RA 诊断研究活动
  • 市场挑战
    • 检测套组的特异性和敏感性的限制

波特五力：开拓类类风湿性关节炎诊断测试市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对类风湿性关节炎诊断测试市场的影响

外部宏观环境因素在塑造类风湿性关节炎诊断测试市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解类风湿性关节炎诊断检测市场的竞争状况

对类风湿性关节炎诊断测试市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵类风湿性关节炎诊断测试市场供应商绩效评估

FPNV 定位矩阵是评估类风湿性关节炎诊断测试市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘类风湿性关节炎诊断测试市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对类风湿性关节炎诊断测试市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地类风湿性关节炎的盛行率正在增加。
      • 增加 RA 治疗和管理的支出
      • 政府和国际组织进行有关 RA 的宣传活动
    • 抑制因素
      • 患者不愿接受 RA 医疗服务
    • 机会
      • 改进 MRI、超音波和 HR-pQCT影像检查并开发血清生物标记组
      • 正在进行的 RA 诊断研究活动
    • 任务
      • 检测套组特异性和敏感性的局限性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依测试类型类风湿性关节炎诊断测试市场

  • 类风湿性关节炎治疗效果监测试验
    • 肌酸酐测试
    • 肌酶测试
    • 水杨酸含量计数
  • 血清检测
    • 抗环瓜氨酸肽
    • 抗核抗体
    • 红血球沉积速率
    • 类风湿因子（RF）
    • 尿酸

第七章类类风湿性关节炎诊断测试市场：依最终用户分类

  • 诊断中心
  • 医院/诊所

第八章北美和南美类风湿性关节炎诊断检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区类风湿性关节炎诊断检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲类风湿性关节炎诊断检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Apollo Health and Lifestyle Limited
  • Arthritis Society Canada
  • Augurex Life Sciences Corporation
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • Laboratory Corporation of America Holdings
  • QIAGEN GmbH
  • Remission Medical
  • Siemens Healthineers
  • Svar Life Sciences AB
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-02026C4CB667

The Rheumatoid Arthritis Diagnosis Tests Market was valued at USD 2.98 billion in 2023, expected to reach USD 3.08 billion in 2024, and is projected to grow at a CAGR of 4.69%, to USD 4.11 billion by 2030.

Rheumatoid Arthritis (RA) diagnosis tests encompass a range of diagnostic procedures aimed at detecting RA's presence and progression, a chronic autoimmune disorder affecting joints. The necessity for these tests arises from RA's impact on quality of life and potential to cause joint damage and systemic complications if untreated. Key applications include blood tests such as rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody testing, and imaging tests like X-rays and MRIs. End-use spans across hospitals, diagnostic laboratories, and academic research institutes. Market growth is primarily driven by increasing RA prevalence, improvements in diagnostic technologies, and heightened awareness among patients and healthcare providers. The aging population and advancements in biomarkers contribute to market expansion. Emerging opportunities exist in developing rapid, accurate, minimally invasive diagnostic tests, and expanding telemedicine applications for remote monitoring.

KEY MARKET STATISTICS
Base Year [2023] USD 2.98 billion
Estimated Year [2024] USD 3.08 billion
Forecast Year [2030] USD 4.11 billion
CAGR (%) 4.69%

However, market growth is impeded by challenges such as high costs of advanced diagnostic tests, risk of false positives or negatives, and limited awareness in low-income regions. Reimbursement issues can also limit test accessibility. To address these challenges, innovation should focus on cost-effective diagnostic solutions, enhancing the sensitivity and specificity of the tests, and increasing patient access through digital health platforms. Collaboration between diagnostic companies, healthcare providers, and technology firms can foster breakthroughs in diagnostic accuracy and accessibility. Concurrently, a focus on personalized healthcare using AI and genetic research holds promise for tailored RA management. Research into novel biomarkers and integration of multi-omic approaches also represents fertile ground for innovation. As the market is competitive and technology-driven, businesses that invest in emerging technologies, prioritize partnerships, and address regional healthcare disparities could strengthen their market position. In summary, the RA diagnosis test market is poised for growth through technological advancements and strategic initiatives despite facing challenges related to cost and accessibility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rheumatoid Arthritis Diagnosis Tests Market

The Rheumatoid Arthritis Diagnosis Tests Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of rheumatoid arthritis worldwide
    • Growing expenditure for the treatment and management of RA
    • Awareness initiatives about RA by governments and global institutions
  • Market Restraints
    • Patients' reluctance to access healthcare services for RA
  • Market Opportunities
    • Improvements in MRI, ultrasound, and HR-pQCT imaging tests and development of serum biomarker panel
    • Ongoing research activities for the diagnosis of RA
  • Market Challenges
    • Limited specificity and sensitivity of test kits

Porter's Five Forces: A Strategic Tool for Navigating the Rheumatoid Arthritis Diagnosis Tests Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rheumatoid Arthritis Diagnosis Tests Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rheumatoid Arthritis Diagnosis Tests Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rheumatoid Arthritis Diagnosis Tests Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rheumatoid Arthritis Diagnosis Tests Market

A detailed market share analysis in the Rheumatoid Arthritis Diagnosis Tests Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rheumatoid Arthritis Diagnosis Tests Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rheumatoid Arthritis Diagnosis Tests Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rheumatoid Arthritis Diagnosis Tests Market

A strategic analysis of the Rheumatoid Arthritis Diagnosis Tests Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rheumatoid Arthritis Diagnosis Tests Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apollo Health and Lifestyle Limited, Arthritis Society Canada, Augurex Life Sciences Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Exagen Inc., F. Hoffmann-La Roche AG, Genway Biotech, Inc., Laboratory Corporation of America Holdings, QIAGEN GmbH, Remission Medical, Siemens Healthineers, Svar Life Sciences AB, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Rheumatoid Arthritis Diagnosis Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Monitoring Rheumatoid Arthritis Treatment Efficiency Tests and Serology Test. The Monitoring Rheumatoid Arthritis Treatment Efficiency Tests is further studied across Creatinine Test, Muscle Enzyme Tests, and Salicylate Level Count. The Serology Test is further studied across Anti-Cyclic Citrullinated Peptide, Antinuclear Antibody, Erythrocyte Sedimentation Rate, Rheumatoid Factor (RF), and Uric Acid.
  • Based on End-User, market is studied across Diagnostic Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rheumatoid arthritis worldwide
      • 5.1.1.2. Growing expenditure for the treatment and management of RA
      • 5.1.1.3. Awareness initiatives about RA by governments and global institutions
    • 5.1.2. Restraints
      • 5.1.2.1. Patients' reluctance to access healthcare services for RA
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in MRI, ultrasound, and HR-pQCT imaging tests and development of serum biomarker panel
      • 5.1.3.2. Ongoing research activities for the diagnosis of RA
    • 5.1.4. Challenges
      • 5.1.4.1. Limited specificity and sensitivity of test kits
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Rheumatoid Arthritis Diagnosis Tests Market, by Test Type

  • 6.1. Introduction
  • 6.2. Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
    • 6.2.1. Creatinine Test
    • 6.2.2. Muscle Enzyme Tests
    • 6.2.3. Salicylate Level Count
  • 6.3. Serology Test
    • 6.3.1. Anti-Cyclic Citrullinated Peptide
    • 6.3.2. Antinuclear Antibody
    • 6.3.3. Erythrocyte Sedimentation Rate
    • 6.3.4. Rheumatoid Factor (RF)
    • 6.3.5. Uric Acid

7. Rheumatoid Arthritis Diagnosis Tests Market, by End-User

  • 7.1. Introduction
  • 7.2. Diagnostic Centers
  • 7.3. Hospitals & Clinics

8. Americas Rheumatoid Arthritis Diagnosis Tests Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Rheumatoid Arthritis Diagnosis Tests Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Rheumatoid Arthritis Diagnosis Tests Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Apollo Health and Lifestyle Limited
  • 3. Arthritis Society Canada
  • 4. Augurex Life Sciences Corporation
  • 5. Beckman Coulter, Inc.
  • 6. Bio-Rad Laboratories Inc.
  • 7. Exagen Inc.
  • 8. F. Hoffmann-La Roche AG
  • 9. Genway Biotech, Inc.
  • 10. Laboratory Corporation of America Holdings
  • 11. QIAGEN GmbH
  • 12. Remission Medical
  • 13. Siemens Healthineers
  • 14. Svar Life Sciences AB
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET RESEARCH PROCESS
  • FIGURE 2. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET DYNAMICS
  • TABLE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CREATININE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MUSCLE ENZYME TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SALICYLATE LEVEL COUNT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTI-CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ERYTHROCYTE SEDIMENTATION RATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR (RF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY URIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023